Why Aerpio Shares Are Skyrocketing Today
Why Aerpio Shares Are Skyrocketing Today
Shares of microcap biopharma Aerpio Pharmaceuticals, Inc. (ARPO) are advancing strongly Thursday on above-average volume.
微盤生物製藥股份Aerpio製藥公司(ARPO)週四以高於平均水平的成交量強勁推進。
The upside in reaction a positive analyst action. H.C. Wainwright analyst Robert Burns upgraded Aerpio from Neutral to Buy and instituted a post-merger price target of $22 per share.
反應中的利好因素是分析師的積極行動。H.C.Wainwright分析師羅伯特·伯恩斯(Robert Burns)將Aerpio的評級從中性上調至買入，並設定了合併後每股22美元的目標價。
Aerpio announced a reverse merger transaction in May under which it will combine with privately-held Aadi Bioscience. Following the merger, Aerpio will change its name to Aadi Bioscience and trade on the Nasdaq under the ticker symbol AADI. The combined company will focus on advancing Aadi's lead product candidate FYARRO.
Aerpio在5月份宣佈了一項反向合併交易，根據該交易，它將與私人持股的Aadi Bioscience合併。合併後，Aerpio將更名為Aadi Bioscience，並在納斯達克交易，股票代碼為AADI。合併後的公司將專注於推進AADI的主要候選產品FYARRO。
Related Link: 14 Biotech Stocks To Watch Over The Next 6 Months
相關鏈接：未來6個月關注的14只生物科技股
The Aadi Bioscience transaction appears transformative, allowing rapid advancement in oncology, Burns said in the upgrade.
伯恩斯在升級中説，Aadi Bioscience交易似乎具有變革性，允許腫瘤學的快速發展。
In a Schedule 14A filing with the SEC, Aerpio has scheduled a special meeting of shareholders at 10 am on Aug. 17, wherein shareholders will be asked to vote on certain proposals necessary for the consummation of the transaction.
在提交給美國證券交易委員會(SEC)的附表14A文件中，Aerpio計劃在8月17日上午10點召開特別股東大會，屆時股東將被要求就完成交易所需的某些提案進行投票。
Aerpio also said its board has unanimously approved the transaction.
Aerpio還表示，其董事會已一致批准了這筆交易。
At last check, Aerpio shares were soaring 61.4% at $2.76.
據最新消息，Aerpio股價飆升61.4%，至2.76美元。